Search Results - Parsons‐Rich, D.

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)

    Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L) by Parsons‐Rich, D., Hua, F., Li, G., Kantaridis, C., Pittman, D. D., Arkin, S.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXaI16L) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

    Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXaI16L) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers by Arkin, Steven, Hua, Fei, Kantaridis, Constantino, Li, Gang, Parsons-Rich, Dana, Pittman, Debra D

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Caractérisation du profil de tolérance de l’évobrutinib chez plus de 1000 patients issus d’études cliniques de phase 2 sur la sclérose en plaques, la polyarthrite rhumatoïde et le lupus érythémateux disséminé

    Caractérisation du profil de tolérance de l’évobrutinib chez plus de 1000 patients issus d’études cliniques de phase 2 sur la sclérose en plaques, la polyarthrite rhumatoïde et le... by Montalban, Xavier, Wallace, Daniel, Genovese, Mark, Tomic, Davorka, Parsons-Rich, Dana, Guehring, Hans

    Published in Revue neurologique
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: